IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA (NYSE:IQV) will release its Q2 2026 financial results before the market opens on Tuesday, July 28, 2026. Management will host a conference call and webcast at 9:00 a.m. ET, with materials and replay available on the IQVIA investor relations website.
IQVIA (NYSE:IQV) and Wiley released a cross-sector report, “Scientific Discovery & AI: The Science-to-Patient Journey.” The report distills insights from a May 2026 summit with 25+ senior leaders across pharma, academia, health systems, technology and publishing.
It highlights AI’s role across four stages of the healthcare value chain and five high-potential directions, while also noting incentive misalignments that can slow patient impact.
IQVIA (NYSE:IQV) priced an offering of €950 million senior notes due 2033 through its subsidiary IQVIA Inc. The notes carry a 4.625% coupon, pay interest semi-annually from December 15, 2026, and are expected to close around June 11, 2026.
Proceeds will refinance existing debt and cover related fees.
IQVIA (NYSE:IQV) plans an offering of €950,000,000 senior notes due 2033 through subsidiary IQVIA Inc. Proceeds are expected to refinance existing indebtedness and cover related fees and expenses.
The notes will be sold in a private placement under Rule 144A and Regulation S, subject to market and customary conditions.
IQVIA (NYSE:IQV) announced that chairman and CEO Ari Bousbib will speak at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:20 a.m. ET.
A live audio webcast and same-day replay will be accessible via the IQVIA investor relations website.
IQVIA (NYSE:IQV) and Kexing Biopharm (688136.SH) are expanding a strategic collaboration to support a global, multi-product biosimilar development and commercialization program. The alliance combines IQVIA’s end-to-end clinical, regulatory, analytics and commercialization capabilities with its AI-enabled clinical trial platform to streamline protocol design, site selection and study conduct for Kexing’s international expansion.
IQVIA (NYSE:IQV) said its board approved a $2.0 billion increase to its share repurchase authorization, raising the remaining Repurchase Program capacity to $3.2 billion as of May 7, 2026.
The program has no expiration date, may be suspended or modified, and repurchases may occur in open‑market, block or private transactions at management's discretion.
IQVIA (NYSE:IQV) announced that CFO Mike Fedock will speak at the Bank of America Health Care Conference in Las Vegas on May 13, 2026 at 1:40 p.m. ET. A live audio webcast and same-day replay will be available via IQVIA's Investor Relations website.
IQVIA (NYSE:IQV) reported first-quarter 2026 results: revenue of $4,151 million (+8.4% reported, +6.0% cc), GAAP net income of $274 million, adjusted EBITDA of $932 million, and adjusted diluted EPS of $2.90. R&D contracted backlog was $34.2 billion.
Operating cash flow was $618 million, free cash flow $491 million (100% of adjusted net income); repurchased $552 million of stock. Full‑year revenue and adjusted EBITDA guidance reaffirmed; adjusted diluted EPS guidance raised to $12.65–$12.95.
IQVIA (NYSE:IQV) will report first-quarter 2026 results before market open on Tuesday, May 5, 2026, and will host a conference call and webcast at 9:00 a.m. ET.
Financials, presentation slides, registration details, live webcast and replay will be available on the IQVIA Investor Relations website. Registered callers receive dial-in, passcode and registrant ID by email.